A multi‑stage pre‑clinical program was conducted: (i) in‑silico docking and molecular dynamics to predict binding affinity; (ii) biochemical kinase assays to assess selectivity; (iii) cellular viability, apoptosis, and cell‑cycle analyses in a panel of 12 cancer cell lines; (iv) pharmacokinetic (PK) profiling in Sprague‑Dawley rats; (v) efficacy and safety evaluation in xenograft mouse models of KRAS‑mutant pancreatic ductal adenocarcinoma (PDAC) and BRAF‑mutant melanoma.
Mukd‑546: Pre‑clinical Evaluation of a Novel Small‑Molecule Inhibitor of the MAPK/ERK Pathway for Targeted Cancer Therapy mukd-546
MUKD-546 was officially released on June 13, 2025, with expanded availability on major platforms and DVD retailers starting June 17, 2025. The production is notable for its substantial runtime, lasting approximately (3 hours and 30 minutes), which is typical for "orgy" themed releases that aim to provide an immersive experience. Plot and Theme Plot and Theme ¹ Department of Pharmacology, University
¹ Department of Pharmacology, University of Cambridge, UK ² Institute of Molecular Medicine, Shanghai Jiao Tong University, China ³ Center for Cancer Research, Universidad Nacional Autónoma de México, Mexico ⁴ Department of Chemistry, University of California, San Diego, USA ⁵ Division of Oncology, Seoul National University Hospital, South Korea University of Cambridge
The more context you can provide, the more useful and accurate the report will be.
Biochemical inhibition (IC₅₀) of MEK1/2 and a panel of 30 kinases (including ERK1/2, RAF, AKT, CDKs) was measured using the ADP‑Glo™ assay (Promega) in triplicate.